ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1053

Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients

Huifeng Yun1, Fenglong Xie2, Elizabeth S. Delzell1, Lang Chen3, Emily Levitan1, James Lewis4, Kenneth G. Saag5, Timothy Beukelman6, Kevin L. Winthrop7, John Baddley8 and Jeffrey R. Curtis9, 1Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 8Medicine, University of Alabama at Birmingham, Birmingham, AL, 9University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Medicare, rheumatoid arthritis (RA) and steroids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids (GCs), or features associated with the disease itself.  The selection of RA medications is potentially confounded due to disease activity and severity (i.e. channeling). Physician proclivities to use specific medications have been shown in prior analyses to be partially independent of patient factors and may represent ‘natural variability’ to reduce confounding in observational analyses. Therefore, we evaluated variability in physicians’ proclivity to use oral GCs among older RA patients.

Methods:  Using 2009 Medicare data, we identified patients who had at least two RA diagnosis codes from rheumatologists. We classified patients as oral GC users if they had at least one prescription for >= 30 days’ supply. Rheumatologists were identified in the data using NPI numbers.

We calculated proclivity to use GCs for each rheumatologist as a proportion, computed as the number of their RA patients who used GCs divided by total number of all their RA patients, and categorized each rheumatologist into one of 4 groups based on quartiles. For each rheumatologist, this proportion was plotted against the number of RA patients in their practice.

The analysis was repeated in the subgroup of patients who also used biologics in 2009. Physician variability in steroid use was examined based upon inter-quartile ranges of the proportion of their patients using GCs, as well as measures of central tendency (i.e. skewness and kurtosis). Weighted Kappa statistics evaluated whether assignment of physicians’ steroid proclivity to quartiles was consistent between the main analysis and the subgroup analysis.

Results: We identified 313,108 RA patients (27,474 of whom used biologics) treated by 4,003 rheumatologists in 2009 Medicare data. Overall, 81,422 (26%) pts were oral GC users; 12,306 (44.8%) in the biologic subgroup used GCs.

The proportion of patients using oral GCs was plotted for each U.S. rheumatologist (Figure) and demonstrated substantial variability between physicians. After restricting to patients on biologics, there was greater physician variability in use of GCS for their patients than in the main analysis (not shown). The weighted kappa statistic comparing physician’s proclivity to use GCs using all their RA patients vs. proclivity to use GCs in the biologic-using subgroup was 0.32 (95% confidence limits: 0.30-0.35) indicating low to moderate agreement.

Conclusion: The frequency with which rheumatologists’ prescribe oral GCs for older RA patients was highly variable and was even greater for patients using biologics. Further work is ongoing to examine whether this approach might be effect to reduce unmeasured or residual confounding associated with glucocorticoid use.

Figure: Proportion of rheumatologist’s RA patients on glucocorticoids per practice in 2009


Disclosure:

H. Yun,
None;

F. Xie,
None;

E. S. Delzell,

Amgen,

2;

L. Chen,
None;

E. Levitan,

Amgen,

2;

J. Lewis,

Pfizer, Prometheus, Lilly, Shire, Nestle, Janssen, AstraZeneca, Amgen,

5,

Centocor, Shire, Takeda,

2;

K. G. Saag,

Ardea; Regeneron; Savient; Takeda,

5,

Ardea; Regeneron; Savient: Takeda,

2;

T. Beukelman,

Genentech and Biogen IDEC Inc.,

5,

Novartis Pharmaceutical Corporation,

5,

Pfizer Inc,

2;

K. L. Winthrop,

Pfizer Inc,

2,

Genentech Inc., Pfizer, UCB, Regeneron,

5;

J. Baddley,

BMS,

2,

Pfizer Inc,

2;

J. R. Curtis,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abb Vie,

2,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abb Vie,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physician-proclivity-to-use-oral-glucocorticoids-among-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology